The FY2025 (Dec) proxy of Aurinia Pharmaceuticals names 20 peer companies for pay. Among Aurinia Pharmaceuticals and these peers, CEO pay was 7th highest of 10 and total shareholder return was 7th highest of 10.
7th highest of 10in Aurinia Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$1.7M$9.7M
7th highest of 10in Aurinia Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$75$364
Pay peer group, FY2025 (Dec) proxy
| ARS Pharmaceuticals | ||
| Travere Therapeutics | ||
| Arcutis Biotherapeutics | ||
| Mimedx Group | ||
| Tarsus Pharmaceuticals | ||
| Evolus | ||
| Innoviva | ||
| UroGen Pharma | ||
| Collegium Pharmaceutical | ||
| Ani Pharmaceuticals | Not disclosed | Not disclosed |
| Aquestive Therapeutics Inc. | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals Inc. | Not disclosed | Not disclosed |
| Ironwood Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Lexicon Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Liquidia | Not disclosed | Not disclosed |
| Pacira BioSciences | Not disclosed | Not disclosed |
| Phathom Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics Inc. | Not disclosed | Not disclosed |
| Siga Technologies Inc. | Not disclosed | Not disclosed |
| Y-mAbs Therapeutics, Inc. | Not disclosed | Not disclosed |
20 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.